These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 1425883

  • 1. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.
    Pazzucconi F, Mannucci L, Mussoni L, Gianfranceschi G, Maderna P, Werba P, Franceschini G, Sirtori CR, Tremoli E.
    Eur J Clin Pharmacol; 1992; 43(3):219-23. PubMed ID: 1425883
    [Abstract] [Full Text] [Related]

  • 2. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients.
    Waysbort J, Schwartz S, Brunner D.
    Arzneimittelforschung; 1994 Nov; 44(11):1217-22. PubMed ID: 7893284
    [Abstract] [Full Text] [Related]

  • 3. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, Morgan J, Wood GN.
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [Abstract] [Full Text] [Related]

  • 4. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S, Barradas MA, Mikhailidis DP, Dandona P.
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [Abstract] [Full Text] [Related]

  • 5. Effect of bezafibrate treatment on the altered lipoprotein profiles in hypertriglyceridemic subjects.
    Norioka M, Suzuki M, Ryomoto K, Ikebuchi M, Harano Y.
    J Atheroscler Thromb; 2000 Jul; 7(4):198-202. PubMed ID: 11521682
    [Abstract] [Full Text] [Related]

  • 6. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH, Durrington PN, Bhatagnar D, Ishola M, Mackness M, Arrol S, Anderson DC.
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [Abstract] [Full Text] [Related]

  • 7. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M, Cofrancesco E, Boschetti C, Cortellaro F, Mancini M, Mariani M, Paoletti R.
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [Abstract] [Full Text] [Related]

  • 8. Double-blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins, and fibrinogen in hyperlipidaemic type 1 diabetes mellitus.
    Winocour PH, Durrington PN, Bhatnagar D, Ishola M, Arrol S, Lalor BC, Anderson DC.
    Diabet Med; 1990 Apr; 7(8):736-43. PubMed ID: 2147637
    [Abstract] [Full Text] [Related]

  • 9. The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia.
    Almér LO, Kjellström T.
    Atherosclerosis; 1986 Jul; 61(1):81-5. PubMed ID: 3524588
    [Abstract] [Full Text] [Related]

  • 10. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V, Wechsler JG, Klör HU, Ditschuneit H.
    Arzneimittelforschung; 1983 Jul; 33(8):1185-90. PubMed ID: 6685498
    [Abstract] [Full Text] [Related]

  • 11. Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy.
    de Man FH, Jonkers IJ, Schwedhelm E, Smelt AH, Onkenhout W, van Duyvenvoorde W, Buytenhek R, Leuven JA, Troost R, van Der Laarse A, Princen HM.
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2434-40. PubMed ID: 11073849
    [Abstract] [Full Text] [Related]

  • 12. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K, Sasaki J, Arakawa K.
    Clin Ther; 1989 Nov; 11(3):331-40. PubMed ID: 2743372
    [Abstract] [Full Text] [Related]

  • 13. Activated platelets in patients with severe hypertriglyceridemia: effects of triglyceride-lowering therapy.
    de Man FH, Nieuwland R, van der Laarse A, Romijn F, Smelt AH, Gevers Leuven JA, Sturk A.
    Atherosclerosis; 2000 Oct; 152(2):407-14. PubMed ID: 10998469
    [Abstract] [Full Text] [Related]

  • 14. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.
    Avellone G, Di Garbo V, Cordova R, Piliego T, Raneli G, De Simone R, Bompiani GD.
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):543-8. PubMed ID: 7578896
    [Abstract] [Full Text] [Related]

  • 15. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia.
    Bradford RH, Goldberg AC, Schonfeld G, Knopp RH.
    Atherosclerosis; 1992 Jan; 92(1):31-40. PubMed ID: 1575820
    [Abstract] [Full Text] [Related]

  • 16. Effects of bezafibrate on lipoprotein subclasses and inflammatory markers in patients with hypertriglyceridemia--a nuclear magnetic resonance study.
    Ikewaki K, Noma K, Tohyama J, Kido T, Mochizuki S.
    Int J Cardiol; 2005 Jun 08; 101(3):441-7. PubMed ID: 15907413
    [Abstract] [Full Text] [Related]

  • 17. Nicotinic acid treatment shifts the fibrinolytic balance favourably and decreases plasma fibrinogen in hypertriglyceridaemic men.
    Johansson JO, Egberg N, Asplund-Carlson A, Carlson LA.
    J Cardiovasc Risk; 1997 Jun 08; 4(3):165-71. PubMed ID: 9475670
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
    Totsuka M, Miyashita Y, Ito Y, Watanabe H, Murano T, Shirai K.
    Atherosclerosis; 2000 Nov 08; 153(1):175-9. PubMed ID: 11058713
    [Abstract] [Full Text] [Related]

  • 19. Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial.
    Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH.
    Am J Med; 2002 Mar 08; 112(4):275-80. PubMed ID: 11893366
    [Abstract] [Full Text] [Related]

  • 20. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
    Vázquez-Chávez C, Salinas-Orozco S, Gómez-Díaz RA, Rosso-Juárez MM, Moreno-Vázquez K, Nissen-Torres T, Argüero-Sánchez R.
    Rev Invest Clin; 1998 Mar 08; 50(6):491-6. PubMed ID: 10070221
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.